Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

AIM: This study evaluated the effects of impaired renal function on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban (10 mg single dose), an oral, direct Factor Xa inhibitor. METHODS: Subjects (n= 32) were stratified based on measured creatinine clearance: healthy controls (≥80 ml mi...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Kubitza, Dagmar, Becka, Michael, Mueck, Wolfgang, Halabi, Atef, Maatouk, Haidar, Klause, Norbert, Lufft, Volkmar, Wand, Dominic D, Philipp, Thomas, Bruck, Heike
Médium: Artigo
Jazyk:Inglês
Vydáno: Blackwell Science Inc 2010
Témata:
Pharmacokinetics
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2997310/
https://ncbi.nlm.nih.gov/pubmed/21039764
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2010.03753.x
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky